Assessment of morbidity from complete axillary dissection
- PMID: 1637663
- PMCID: PMC1977908
- DOI: 10.1038/bjc.1992.230
Assessment of morbidity from complete axillary dissection
Abstract
The importance of axillary dissection as part of the primary surgical procedure in the treatment of operable cases of carcinoma of the breast is established. The morbidity of this procedure, however, is less well documented. A study of 126 women who had had full axillary dissection as part of their initial surgical treatment was undertaken to assess their degree of morbidity in terms of numbness, pain, weakness, swelling, and stiffness. Seventy per cent of cases complained of numbness, 33% of pain, 25% of weakness, 24% of limb swelling, and 15% of stiffness. Objective measurements confirmed decreased sensation in 81%, weakness in 27%, swelling in 10%, and stiffness in 10%. In no case were these symptoms described as severe, though they did have an effect upon the daily lives of 39%. The side effects of full axillary dissection are common and all women should be warned of them prior to surgery; however they are usually mild and therefore should not preclude this procedure as a part of definitive surgical treatment.
Similar articles
-
Morbidity associated with axillary surgery for breast cancer.ANZ J Surg. 2004 May;74(5):314-7. doi: 10.1111/j.1445-1433.2004.02992.x. ANZ J Surg. 2004. PMID: 15144248
-
Eighteen sensations after breast cancer surgery: a comparison of sentinel lymph node biopsy and axillary lymph node dissection.Oncol Nurs Forum. 2002 May;29(4):651-9. doi: 10.1188/02.ONF.651-659. Oncol Nurs Forum. 2002. PMID: 12011912
-
Physical and psychological morbidity after axillary lymph node dissection for breast cancer.J Clin Oncol. 1999 Jan;17(1):143-9. doi: 10.1200/JCO.1999.17.1.143. J Clin Oncol. 1999. PMID: 10458227
-
[Management of the axilla in breast cancer: evidences and unresolved issues].Orv Hetil. 2001 Sep 9;142(36):1941-50. Orv Hetil. 2001. PMID: 11680099 Review. Hungarian.
-
Is axillary lymph node dissection necessary in the routine management of breast cancer? Yes.Important Adv Oncol. 1996:245-50. Important Adv Oncol. 1996. PMID: 8791140 Review.
Cited by
-
Factors Associated with Axillary Lymph Node Status in Clinically Node-Negative Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.Cancers (Basel). 2022 Sep 14;14(18):4451. doi: 10.3390/cancers14184451. Cancers (Basel). 2022. PMID: 36139612 Free PMC article.
-
A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer.Front Endocrinol (Lausanne). 2022 Nov 25;13:1042394. doi: 10.3389/fendo.2022.1042394. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36506067 Free PMC article.
-
Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial?Adv Radiat Oncol. 2018 Apr 24;3(3):258-264. doi: 10.1016/j.adro.2018.03.004. eCollection 2018 Jul-Sep. Adv Radiat Oncol. 2018. PMID: 30197938 Free PMC article.
-
"Prevalence of chronic pain following resection of pelvic bone tumours: A single centre prospective observational survey".Br J Pain. 2022 Jun;16(3):263-269. doi: 10.1177/20494637211047143. Epub 2021 Sep 27. Br J Pain. 2022. PMID: 35646344 Free PMC article.
-
Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy.Breast Cancer Res Treat. 2021 Oct;189(3):837-843. doi: 10.1007/s10549-021-06341-1. Epub 2021 Aug 3. Breast Cancer Res Treat. 2021. PMID: 34342766
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical